OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 16.6% in April

OPKO Health, Inc. (NASDAQ:OPK) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 78,030,000 shares, a drop of 16.6% from the March 31st total of 93,610,000 shares. Currently, 23.8% of the shares of the company are sold short. Based on an average trading volume of 9,110,000 shares, the days-to-cover ratio is presently 8.6 days.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was acquired at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the purchase, the chief executive officer now owns 210,968,225 shares in the company, valued at approximately $183,542,355.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have acquired 4,600,000 shares of company stock valued at $4,393,000. 47.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its stake in OPKO Health by 5.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 437,276 shares of the biotechnology company’s stock worth $525,000 after purchasing an additional 24,350 shares during the period. SlateStone Wealth LLC bought a new position in shares of OPKO Health during the first quarter valued at about $31,000. Assenagon Asset Management S.A. increased its stake in OPKO Health by 107.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,253,808 shares of the biotechnology company’s stock worth $1,502,000 after purchasing an additional 648,569 shares during the period. PFG Investments LLC purchased a new position in shares of OPKO Health in the first quarter worth $1,125,000. Finally, Hennion & Walsh Asset Management Inc. boosted its position in OPKO Health by 11.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company’s stock valued at $931,000 after buying an additional 79,525 shares during the period. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Barrington Research reiterated an “outperform” rating and set a $1.50 price objective on shares of OPKO Health in a research report on Monday, April 1st. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. Piper Sandler reiterated an “overweight” rating and set a $5.00 price objective on shares of OPKO Health in a research report on Monday, April 1st. Finally, StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Friday, March 1st.

OPKO Health Stock Down 1.6 %

OPKO Health stock traded down $0.02 during midday trading on Tuesday, hitting $1.22. 3,098,603 shares of the stock were exchanged, compared to its average volume of 12,871,089. OPKO Health has a 52-week low of $0.85 and a 52-week high of $2.24. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.22. The stock has a market capitalization of $850.33 million, a price-to-earnings ratio of -4.96 and a beta of 1.81.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business had revenue of $181.90 million for the quarter, compared to analyst estimates of $177.53 million. During the same period last year, the company posted ($0.11) earnings per share. OPKO Health’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, research analysts expect that OPKO Health will post -0.33 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.